Otsuka Corporation (TYO:4768)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.17T -7.8% |
| Revenue (ttm) | 1.32T +19.4% |
| Net Income | 64.30B +20.2% |
| EPS | 169.10 +19.9% |
| Shares Out | 379.20M |
| PE Ratio | 18.31 |
| Forward PE | 18.70 |
| Dividend | 95.00 (3.04%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 1,476,400 |
| Average Volume | 1,460,030 |
| Open | 3,094.00 |
| Previous Close | 3,096.00 |
| Day's Range | 3,004.00 - 3,103.00 |
| 52-Week Range | 2,815.00 - 3,654.00 |
| Beta | 0.14 |
| RSI | 41.26 |
| Earnings Date | Feb 1, 2026 |
About Otsuka
Otsuka Corporation, together with its subsidiaries, operates as an information technology (IT) platformer in Japan. It operates through System Integration Business, and Service and Support Business segments. The System Integration Business segment offers management systems and collaborative software, such as ERP packages and groupware to cover a range of specialized fields, including CAD and web technologies; and software, hardware, intranet, and security products for the construction and expansion of computer networks, as well as intermediary ... [Read more]
Financial Performance
In 2025, Otsuka's revenue was 1.32 trillion, an increase of 19.42% compared to the previous year's 1.11 trillion. Earnings were 64.30 billion, an increase of 20.24%.
Financial StatementsNews
EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary angioedema ...
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Otsuka Corp (4768)
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Otsuka Corp (4768)
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop
4D Molecular Therapeutics centers on 4D-150 Wet-AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.
Otsuka Initiates Global Phase 3 Trial Of Repinatrabit For Phenylketonuria
(RTTNews) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced the launch of a global Phase 3 clinical trial for repinatrabit (JN...
FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment
FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment
Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction
FDA approves Otsuka's Voyxact to reduce proteinuria in IgAN patients, showing a 51% drop in trials. Read more here.
FDA Grants Accelerated Approval For Otsuka's VOYXACT In IgAN
(RTTNews) - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...
Otsuka 9-month Profit Rises; Revenue Up 5.1%
(RTTNews) - Otsuka Holdings Co. (4578.T) reported that its nine month profit attributable to owners of the company was 297.7 billion yen, an increase of 55.3% from last year. Earnings per share was 56...
Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka
When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI req...
Vera plunges as Otsuka outperforms with IgA nephropathy therapy
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
The FDA target action date (PDUFA date) is set for November 28, 2025 If approved, sibeprenlimab would offer patients a convenient single-dose prefilled syringe for subcutaneous injection every four we...
Arbitrum DAO mulls winding down unsustainable Web3 gaming fund
Members of Arbitrum’s decentralized autonomous organization (DAO) are discussing a potential clawback of funds allocated to build a gaming ecosystem on the network, citing a lack of progress and trans...
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
Vera plunges as Otsuka updates on rival therapy
Otsuka submits NDA in Japan for the treatment of hypercholesterolemia
Esperion's partner Otsuka submits New Drug Application for bempedoic acid in Japan for hypercholesterolemia treatment.Expansion of market potential.
ICU Medical, Otsuka team up to boost US IV solutions production
Otsuka Is Said to Weigh Sale of Stake in Medical Device Maker MicroPort Scientific
Otsuka Holdings Co. is considering options for its holding in Hong Kong-listed MicroPort Scientific Corp., including selling its stake in the medical device maker, according to people familiar with th...
Citi maintains ‘Sell’ rating on Lupin, sets target at Rs 1,700
Citi has reiterated its “Sell” recommendation for Lupin, with a target price of Rs 1,700 per share. This comes in light of recent developments regarding Lupin’s generic version of Jynarque. Key points...